University of Pittsburgh Cancer Institute (UPCI)

Gretchen Ahrendt, MD, FACS

Gretchen Ahrendt
Associate Professor of Surgery, University of Pittsburgh School of Medicine
Director of Surgical Breast Services, Magee-Womens Hospital of UPMC

Contact Information

Contact Information

UPMC CancerCenter at Magee-Womens Hospital of UPMC
300 Halket Street
Pittsburgh, PA 15213

Phone: 412-641-4530
Email: gahrendt@magee.edu

Research Keywords

Research Keywords

Breast cancer; surgical oncology; neoadjuvant chemotherapy; clinical trials; MRI

Research Summary

Research Summary

Dr. Ahrendt's research interests include the impact of breast MRI on surgical planning for breast cancer and how tumor subtypes respond to neoadjuvant chemotherapy. She believes in incorporating new advances from clinical trials into current treatment of her patients.

Selected Publications

Selected Publications

  • Wesmiller SW, Bender CM, Sereika SM, Ahrendt G, Bonaventura M, Bovbjerg DH, Conley Y. Association between serotonin transport polymorphisms and postdischarge nausea and vomiting in women following breast cancer surgery. Oncol Nurs Forum. 2014 Mar 1;41(2):195-202. PubMed Link
  • Belfer I, Schreiber KL, Shaffer JR, Shnol H, Blaney K, Morando A, Englert D, Greco C, Brufsky A, Ahrendt G, Kehlet H, Edwards RR, Bovbjerg DH. Persistent postmastectomy pain in breast cancer survivors: analysis of clinical, demographic, and psychosocial factors. J Pain. 2013 Oct;14(10):1185-95. PubMed Link
  • Soran A, Ibrahim A, Kanbour M, McGuire K, Balci FL, Polat AK, Thomas C, Bonaventura M, Ahrendt G, Johnson R. Decision making and factors influencing long-term satisfaction with prophylactic mastectomy in women with breast cancer. Am J Clin Oncol. 2013 May 2. PubMed Link
  • Schreiber KL, Martel MO, Shnol H, Shaffer JR, Greco C, Viray N, Taylor LN, McLaughlin M, Brufsky A, Ahrendt G, Bovbjerg D, Edwards RR, Belfer I. Persistent pain in postmastectomy patients: comparison of psychophysical, medical, surgical, and psychosocial characteristics between patients with and without pain. Pain. 2013 May;154(5):660-8. PubMed Link
  • Kraus JA, Beriwal S, Dabbs DJ, Ahrendt GM, McGuire KP, Johnson RR, Badve P, Puhalla SL, Bhargava R. Predictors of pathologic complete response after standard neoadjuvant chemotherapy in triple-negative breast carcinoma. Appl Immunohistochem Mol Morphol. 2012 Jul;20(4):334-9. PubMed Link
  • McGuire KP, Toro-Burguete J, Dang H, Young J, Soran A, Zuley M, Bhargava R, Bonaventura M, Johnson R, Ahrendt G. MRI staging after neoadjuvant chemotherapy for breast cancer: does tumor biology affect accuracy? Ann Surg Oncol. 2011 Oct;18(11):3149-54. PubMed Link
  • Vargo JA, Beriwal S, Ahrendt GM, Soran A, Johnson RR, McGuire K, Bhargava R. Molecular class as a predictor of locoregional and distant recurrence in the neoadjuvant setting for breast cancer. Oncology. 2011;80(5-6):341-9. PubMed Link
  • Dick AW, Sorbero MS, Ahrendt GM, Hayman JA, Gold HT, Schiffhauer L, Stark A, Griggs JJ. Comparative effectiveness of ductal carcinoma in situ management and the roles of margins and surgeons. J Natl Cancer Inst. 2011 Jan 19;103(2):92-104. PubMed Link
  • Bhargava R, Dabbs DJ, Beriwal S, Yildiz IA, Badve P, Soran A, Johnson RR, Brufsky AM, Lembersky BC, McGuire KP, Ahrendt GM. Semiquantitative hormone receptor level influences response to trastuzumab-containing neoadjuvant chemotherapy in HER2-positive breast cancer. Mod Pathol. 2011 Mar;24(3):367-74. PubMed Link
  • Bhargava R, Beriwal S, Dabbs DJ, Ozbek U, Soran A, Johnson RR, Brufsky AM, Lembersky BC, Ahrendt GM. Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapy: a single institutional experience with 359 cases. Cancer. 2010 Mar 15;116(6):1431-9. PubMed Link

See all pubs (Pubmed)

Department Website









Last modified: 8/1/14